Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke
worldwide and confers one of the greatest risks of recurrent stroke compared with other …

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute
myocardial infarction. Recent advances in understanding the molecular basis of the role of …

Background Comparisons between ticagrelor and clopidogrel for the secondary prevention
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …

Background Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after
an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not …

Background Ticagrelor may be a more effective antiplatelet therapy than aspirin for the
prevention of recurrent stroke and cardiovascular events in patients with acute cerebral …

Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …

Background The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the
incidence of major adverse cardiovascular events when administered at hospital admission …

Background Although P2Y12 antagonists are effective in patients with non–ST-segment
elevation (NSTE) acute coronary syndromes, the effect of the timing of administration …

Background Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine
diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet …

Background—Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist. This is
the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using …